focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,983.00
Bid: 1,990.00
Ask: 1,991.00
Change: -45.00 (-2.22%)
Spread: 1.00 (0.05%)
Open: 2,030.00
High: 2,034.00
Low: 1,980.00
Prev. Close: 2,028.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 17th Apr 2013 07:20

African Barrick Gold: Deutsche Bank cuts target price from 230p to 173p, while its hold recommendation is reiterated.Ashmore Group: Morgan Stanley raises target price from 395p to 444p and maintains an equal-weight rating.Ashtead Group: Jefferies increases target price from 615p to 690o and reiterates a buy recommendation.Aquarius Platinum: Investec starts with a target price of 45p and a hold recommendation.British American Tabacco: Nomura lowers target price from 4087p to 4012p, while its buy recommendation remains unchanged.Cello Group: Sanlam Securities initiates with a target price of 75p and a buy recommendation.Derwent London: Investec raises target price from 2275p to 2360p and maintains an add rating.Escher Group Holdings: Panmure Gordon takes target price from 410p to 456p and reiterates a buy recommendation.Falkland Islands Hodlings: WH Ireland cuts target price from 480p to 448p retaining a buy recommendation.Fresnillo: Deutsche Bank takes tatget price from 1260p to 1040p and still recommends selling.Fusion IP: HB Markets initiates with a speculative buy.Hargreaves Lansdown: Jefferies increases target price from 1000p to 1150p, while maintaining a buy recommendation.Hays: HSBC Holdings ups target price from 80p to 106p and leaves its neutral rating unaltered.Hikma Pharmaceuticals: Jefferies reduces target price from 1150p to 1040p keeping a buy recommendation. Panmure Gordon cuts target price from 1100p to 1000p, while its buy recommendation remains unchanged.Imperial Tabacco: Nomura cuts target price from 2443p to 2386p and reiterates a reduce rating.Interbulk Group: Westhouse Securities shifts target price from 11p to 10p and keeps a buy recommendation.InterContinental Hotels Group: Barclays downgrades to equal-weight with a target price of 2085p.JD Sports Fashion: Investec increases target price from 830p to 860p staying with its buy recommendation.Legal & General Group: Investec raises target price from 153p to 193p keeping a hold recommendation.Man Group: Canaccord Genuity raises target price to 120p and upgrades from hold to buy.Michael Page: Jefferies cuts target price from 520p to 500p and retains a buy recommendation. JP Morgan reduces target price from 389p to 370p maintaining a neutral rating. Citigroup lowers target price from 440p to 400p, while leaving its neutral rating unchanged. Credit Suisse moves target price from 400p to 360p and stays with an underperform rating. HSBC Holdings takes target price from 450p to 414p and downgrades to neutral.Moneysupermarket.com: Westhouse Securities moves target price from 195p to 210p and upgrades from neutral to add.Randgold Resources: Deutsche Bank cuts target price from 6030p to 5500p, while maintaining a buy recommendation.Rio Tinto: Deutsche Bank reduces target price from 4521p to 4489p keeping a buy recommendation.Sepura: Investec shifts target price from113p to 115p and leaves its buy recommendation unchanged.Smiths News: N+1 Singer moves target price from 164p to 185p, but downgrades to hold.Speedy Hire: Panmure Gordon shifts target price from 56p to 60p maintaining a buy recommendation.Vodafone Group: Deutsche Bank shifts target price from 173p to 180p and maintains a hold recommendation. HSBC Holdings ups target price from 205p to 230p reiterating an overweight rating.
More News
6 Aug 2021 12:07

LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls

LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls

Read more
6 Aug 2021 09:03

LONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near

LONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near

Read more
6 Aug 2021 08:40

TOP NEWS: Hikma hikes Generics guidance as interim profit swells

TOP NEWS: Hikma hikes Generics guidance as interim profit swells

Read more
6 Aug 2021 07:42

LONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance

LONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance

Read more
6 Aug 2021 07:22

Hikma lifts FY generics guidance as first-half profits, revenue jump

(Sharecast News) - Hikma Pharmaceuticals upgraded full-year guidance for its generics arm and reported a rise in first-half profit and revenue as it hailed a strong performance in both the generics and branded segments, and resilience in the injectables business.

Read more
30 Jul 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
14 Jul 2021 19:38

IN BRIEF: Arecor ends first half of 2021 with solid cash position

IN BRIEF: Arecor ends first half of 2021 with solid cash position

Read more
13 Jul 2021 10:00

BROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight

BROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight

Read more
1 Jul 2021 09:51

BROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart

BROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart

Read more
21 Jun 2021 14:51

UPDATE 1-U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

(Adds background to case, paragraphs 4-10)By Blake BrittainWASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against gener...

Read more
21 Jun 2021 14:31

U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

WASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals PLC and Dr. Reddy's La...

Read more
8 Jun 2021 13:54

Tuesday broker round-up

(Sharecast News) - tinyBuild: Berenberg reiterates buy with a target price of 295p.

Read more
6 May 2021 09:46

BROKER RATINGS: Exane BNP downgrades three property companies

BROKER RATINGS: Exane BNP downgrades three property companies

Read more
30 Apr 2021 17:01

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

Read more
30 Apr 2021 08:58

TOP NEWS: Hikma Pharma confident after promising start to year

TOP NEWS: Hikma Pharma confident after promising start to year

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.